CCA
ZYNE

Cruiser Capital Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Cruiser Capital Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-235
Closed -$5K – 39
2017
Q4 		$5K Buy
+235
New +$2.69K ﹤0.01% 32

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cruiser Capital Advisors's ZYNE Position: Q4 2018 in Review

Cruiser Capital Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2018, closing a stake of 36,888 shares — an estimated $301K sold.

Cruiser Capital Advisors first reported a position in ZYNE in Q4 2017 and held it in 4 quarters. The position peaked at $492K in Q4 2017. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2018.

  • Cruiser Capital Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
  • Cruiser Capital Advisors sold 36,888 Zynerba Pharmaceuticals, Inc shares in Q4 2018, an estimated $301K.
  • Cruiser Capital Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 4 quarters.
  • Cruiser Capital Advisors's Zynerba Pharmaceuticals, Inc position peaked at $492K in Q4 2017.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2018.

Based on Cruiser Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.